Educating pharmacists and the public about the role of over-the-counter medications in the management of Autism Spectrum Disorders

Jillian M. Bankoff
St. John Fisher College, jb05856@students.sjfc.edu

Melinda E. Lull
St. John Fisher College, mlull@sjfc.edu

How has open access to Fisher Digital Publications benefited you?

Follow this and additional works at: http://fisherpub.sjfc.edu/doctoral_ext_pub

Part of the Pharmacy and Pharmaceutical Sciences Commons

Publication Information
http://fisherpub.sjfc.edu/doctoral_ext_pub/4

Please note that the Publication Information provides general citation information and may not be appropriate for your discipline. To receive help in creating a citation based on your discipline, please visit http://libguides.sjfc.edu/citations.

This document is posted at http://fisherpub.sjfc.edu/doctoral_ext_pub/4 and is brought to you for free and open access by Fisher Digital Publications at St. John Fisher College. For more information, please contact fisherpub@sjfc.edu.
Educating pharmacists and the public about the role of over-the-counter medications in the management of Autism Spectrum Disorders

Abstract
Over-the-counter (OTC) medications are used by various populations as an adjunct to help improve various aspects of life, such as sleep cycles, disease prevention, and mood. The purpose of this study is to compile all of the available data from human trials of over-the-counter medications used in patients with Autism Spectrum Disorders (ASD). OTCs have been used in the treatment of ASD to minimize social impairments, suppress repetitive behaviors, and enhance quality of sleep to improve daytime behaviors. Ultimately, the main objectives of this project are to educate pharmacists and the public (both patients and their families) about the role of over-the-counter medications in the treatment and management of ASD.

Disciplines
Pharmacy and Pharmaceutical Sciences

Comments
Poster presented at the American Society of Health Systems Pharmacy Midyear Clinical Meeting in Anaheim, California, December 2014.

This poster presentation is available at Fisher Digital Publications: http://fisherpub.sjfc.edu/doctoral_ext_pub/4
The purpose of this study is to compile all of the available data from human trials of over-the-counter medications used in patients with Autism Spectrum Disorders (ASD). OTCs have been used in the treatment of ASD to minimize social impairments, suppress repetitive behaviors, and enhance quality of sleep to improve daytime behaviors. Ultimately, the main objectives of this project are to educate pharmacists and the public (both patients and their families) about the role of over-the-counter medications in the treatment and management of ASD.

**Objective**

Over-the-counter (OTC) medications are used by various populations as an adjunct to help improve various aspects of life, such as sleep cycles, disease prevention, and mood. The purpose of this study is to compile all of the available data from human trials of over-the-counter medications used in patients with Autism Spectrum Disorders (ASD). OTCs have been used in the treatment of ASD to minimize social impairments, suppress repetitive behaviors, and enhance quality of sleep to improve daytime behaviors. Ultimately, the main objectives of this project are to educate pharmacists and the public (both patients and their families) about the role of over-the-counter medications in the treatment and management of ASD.

**Methods**

All clinical trials regarding the use of OTC medications in ASD were found using PubMed, MedlinePlus, and primary literature sources found in a public library. From these trials, data was recorded based on the type of study, objective, sample size, the behavior that was measured, and final results and conclusions. After data collection and compilation, materials will be developed for dissemination to pharmacists and the public. This study includes preparing informational pamphlets for pharmacists and the public about the role of OTC medications in the treatment and management of ASD.

**Results**

**Melatonin**
- Hypothesized MOA for ASD: Reduces the amount of time it takes to fall asleep and increases duration of sleep leading to better daytime behavior
- Side effects include:
  - Nausea and sleep walking
- Studied dose ranges: 0.75mg-25mg

**Vitamin C**
- Hypothesized MOA for ASD: Improvements in stereotypical behaviors including rocking, pacing, flapping, and whirling
- Side effects include:
  - Diarrhea, nausea, cramping, and nephrolithiasis
- Studied dose: 114mg/kg/day

**Vitamin B₆ and Magnesium**
- Hypothesized MOA for ASD: Improvements in speech and language and reduction in hyperactivity
- Side effects include:
  - Nausea, photosensitivity, peripheral neuropathy (Vitamin B₆), and diarrhea (Magnesium)
- Studied dose ranges: 2.9-30mg/Kg (Vitamin B₆) and 1.4-10mg/Kg (Magnesium)

**Omega-3 Fatty Acids**
- Hypothesized MOA for ASD: Reduce hyperactivity and mitigate social impairments
- Side effects include:
  - Belching, indigestion, and diarrhea
- Studied dose ranges: 200mg-1.3 g/day

**Conclusions**

- Data is incomplete based on the number of trials available and the number of ASD participants. Further studies are required prior to any definitive conclusions.
- Future directions:
  - Summaries and informational pamphlets will be distributed to caregivers of children with ASD.
  - Further research will be conducted on the following heralbs/OTCs: Vitamin B₁₂, Tetrahydrobiopterin, Carnitine, and Vitamin A
  - A CE for pharmacists will be created.

**References**


**OTC/Herbal**

<table>
<thead>
<tr>
<th>OTC/Herbal</th>
<th>Number of Studies</th>
<th>Number of Participants</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melatonin</td>
<td>39</td>
<td>879</td>
<td>21 out of 39 studies showed improved sleep duration.</td>
</tr>
<tr>
<td>Vitamin C</td>
<td>3</td>
<td>37</td>
<td>All studies showed positive result by reducing severity of repetitive behaviors.</td>
</tr>
<tr>
<td>Vitamin B₆ and Magnesium</td>
<td>21</td>
<td>493</td>
<td>17 of 21 studies showed some improvement, whereas 4 showed no significant difference.</td>
</tr>
<tr>
<td>Omega-3 Fatty Acids</td>
<td>11</td>
<td>339</td>
<td>4 studies showed insignificance; all other studies were inconclusive and require larger sample sizes.</td>
</tr>
</tbody>
</table>

**Table 1: Compiled results of primary literature with OTC use in ASD.**

*Note: this is not a comprehensive list of the OTCs studied in the treatment of ASD.*